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Introduction
Tumor microenvironments possess complex chemokine net-
works that contribute to the extent and phenotype of the host 
infiltrate (1–3). In addition, malignant cells may gain function-
al chemokine receptors, often as a consequence of oncogenic 
mutations, allowing them to respond to distant chemokine gra-
dients during metastatic spread (4, 5).
The chemokine receptor CCR4 is expressed on circulating 
and tissue-resident T cells, being predominantly associated with a 
Th2 phenotype (6–8), as well as on other T helper cells (9). CCR4 
is also highly expressed on circulating Tregs and on Tregs recruit-
ed at tumor sites in ovarian cancer (10) and in glioblastoma (11). In 
ovarian cancer, the CCR4 ligand CCL22 is found both in the tumor 
tissue and in macrophages isolated from ascitic fluid (9). In hepa-
tocellular carcinoma, malignant cell–produced CCL22 recruited 
CCR4+ Tregs that facilitated immune escape of malignant cells 
(12). Similarly, in breast cancer, CCR4+ Tregs, recruited by CCL22 
in the tumor microenvironment, are predictive of a worse progno-
sis (13). A second breast cancer study found reduced overall sur-
vival and high CCR4 expression in tumor biopsies (14). Finally, 
in a cohort of 753 patients with gastric adenocarcinoma, positive 
staining for CCR4 was also associated with a poorer prognosis (15).
CCR4 also plays a role in hematological malignancies, and there 
are now clinical trials of an anti-CCR4 antibody, mogamulizumab, 
that has enhanced antibody-dependent cell-mediated cytotoxicity 
(ADCC) activity. Mogamulizumab is approved in Japan for the treat-
ment of relapsed adult T cell leukemia (ATL) (16) and has also been 
tested in patients with relapsed peripheral T cell lymphoma (PTLC) 
and cutaneous T cell lymphoma (CTLC) (17). The treatment is indi-
cated for patients with CCR4-positive leukemia cells, but might 
also act by reducing the number of Tregs in cancer patients (18).
In this article, we have investigated CCR4 as a target in renal 
cell carcinoma (RCC) using patient samples and an orthotopic 
mouse RCC model. We have found abnormal levels of CCR4 
and its ligands in human RCC biopsies and plasma samples. In 
preclinical experiments we found that Affi-5, a fully human anti-
CCR4 antibody with antagonistic activity (described in ref. 19), 
has antitumor activity in a renal cancer model. Inhibition of CCR4 
did not reduce the proportion of CCR4-positive infiltrating leuko-
cytes in the tumor microenvironment but altered the phenotype 
of the immune infiltrate, affecting in particular the phenotype of 
myeloid cells and increasing the number of infiltrating NK cells. 
These effects were dependent on the adaptive immune system 
and required functioning CD4+ T cells. The antibody also altered 
the phenotype of tumor-associated macrophages (TAMs) in the 
B16 melanoma model. Inhibition of CCR4, alone or in combina-
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B–D), suggesting that CCR4 may be important in the trafficking of 
tumor-associated leukocytes.
The CCR4 ligands CCL22 (also known as MDC) and CCL17 
(also known as TARC) were also expressed in the RCC tumors 
(Figure 1B and Supplemental Figure 1A). CCR4 was weakly 
expressed in normal kidney, but the ligands could be detected in 
normal kidney tubules (Supplemental Figure 1A).
We next compared plasma concentrations of CCL17 and CCL22 
from patients with advanced RCC with age-matched controls using 
the Meso Scale Discovery electrochemiluminescence system. 
The concentration of CCL17 in plasma was significantly higher in 
patients; however, the concentration of CCL22 was significantly 
lower in the patients compared with controls (Figure 1, C and D). 
The CCL17/CCL22 ratio was also significantly different between 
the 2 groups and 4-fold higher in patients compared with controls 
(Figure 1E). Moreover, a high CCL17/CCL22 ratio correlated with 
lower progression-free and overall survival rates (Figure 1, F and G), 
but this association was not seen if the individual chemokines were 
tion with other immune modulators, may be a valuable therapeutic 
approach in human cancers with high levels of CCR4 in the tumor 
microenvironment and abnormal plasma CCR4 ligand levels.
Results
CCR4 and its ligands in human renal cell carcinoma. This study 
was prompted by the finding of abundant CCR4 mRNA in biop-
sies from renal cancers as compared with normal kidney (Figure 
1A). CCR4 protein was also detected by IHC on malignant cells 
and leukocytes in a tissue microarray (TMA) constructed from 
57 advanced RCC patient biopsies (Figure 1B and Supplemental 
Figure 1A; supplemental material available online with this arti-
cle; https://doi.org/10.1172/JCI82976DS1). Of the 173 cores in 
the TMA, 157 showed positive CCR4 staining. 75% of the biop-
sies were classified as clear cell, with others classified as papil-
lary RCC. There was a significant positive correlation between 
CCR4 positivity and the extensive T cell (CD3+) or macrophage 
(CD68+) infiltrates in the tumor cores (Supplemental Figure 1, 
Figure 1. Abnormal expression of CCR4 
and its ligands in human renal cancer. (A) 
CCR4 mRNA was measured by real-time 
RT-PCR in RCC biopsies and compared with 
normal kidney. (B) Levels of CCR4 and its 
ligands CCL17 and CCL22 were analyzed by 
IHC in a TMA of renal cancer biopsies from 
human patients. Each biopsy was scored 
0, no staining; 1, weak staining; 2, strong 
staining for CCR4, CCL17, and CCL22. A 
total of 173 biopsy cores from 57 patients 
were stained for CCR4 and CCL22, and 145 
cores from 48 patients for CCL17. (C–E) 
Plasma levels of CCL17 and CCL22 and the 
CCL17/CCL22 ratio in RCC patient plasma 
were compared with those from normal 
individuals of matched age using Meso 
Scale Discovery System Ultra-Sensitive 
plates. n = 47 for RCC patients, n = 26 for 
normal individuals; 2-tailed Student’s t 
test, ***P = 0.0001 for CCL17 (C), CCL22 (D), 
and CCL17/CCL22 (E). (F and G) Kaplan-Mei-
er survival curves for progression-free sur-
vival (PFS; F) and overall survival (OS; G) for 
RCC patients with CCL17/CCL22 high (above 
the median) or low (n = 57). For progres-
sion-free survival, hazard ratio 0.436, 95% 
CI 0.239–0.797; for overall survival, hazard 
ratio 0.552, 95% CI 0.306–0.995.
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determined by flow cytometry. The human cell lines had detectable 
intracellular CCL17 and CCL22 (Supplemental Figure 2), and these 
chemokines were also present in the tissue culture medium during 3 
days of incubation (CCL17 300 pg/106 cells, CCL22 2 ng/106 cells). 
RENCA cells also secreted CCL17 (200 pg/106 cells) and CCL22 (10 
pg/106 cells) in the medium during 3 days of incubation.
Both CCR4 ligands stimulated migration of the human cell 
line 786-O (Supplemental Figure 3, A and B). Similar data were 
examined (Supplemental Figure 1, E and F), suggesting that activi-
ty of both chemokines is important in RCC biology. In our cohort, 
CCR4 expression, as determined by IHC on the TMAs, was not pre-
dictive of clinical outcome (data not shown).
Renal cancer cell lines have functional CCR4 receptors. As we had 
detected CCR4 and its ligands in malignant cells in tumor biopsies, 
we next studied RCC cancer cell lines. RCC cell lines 786-O and 
A498 (human) and RENCA (murine) expressed cell surface CCR4 as 
Figure 2. Anti-CCR4 antibody Affi-5 has antitumor activity in the RENCA RCC model. (A) Migration of RENCA cells in response to mouse CCL17 in the 
presence of 10 μg/ml Affi-5 or isotype control IgG after an incubation of 16 hours was analyzed with a migration assay. Significant difference compared with 
CCL17-induced migration in the presence of isotype control is indicated; 2-tailed Student’s t test, **P < 0.01. One experiment representative of 3 is shown.  
(B and C) BALB/c mice were injected with 1 × 105 RENCA-luc cells and treated twice weekly with Affi-5 (T) or isotype control (C) at 20 mg/kg starting 48 hours 
after surgery. Mice were sacrificed 17 days after surgery, and tumor weight was determined. Combined results of 6 experiments are shown (n = 39 C, n= 43 
T, 2-tailed Student’s t test, ***P = 0.0003). (C) Chemiluminescence was determined on days 7, 14, and 17, and one representative experiment is reported in 
the graph and images as relative luminescence units. 2-tailed Student’s t test, *P = 0.029 on day 17. (D) BALB/c mice were injected with 1 × 105 RENCA-luc 
cells and treated twice weekly with Affi-5 (T) or isotype control (C) at 10 mg/kg starting 48 hours after surgery. Mice were sacrificed 17 days after surgery, and 
tumor weight was determined. Combined results of 6 experiments are shown (n = 39 C, n = 43 T, 2-tailed Student’s t test, ***P < 0.0001). (E and F) Serum 
collected at end point was analyzed by ELISA for CCL17 and CCL22. Two-tailed Student’s t test, *P = 0.05, n = 5 for samples from control-treated (C) mice;  
n = 4 for samples from Affi-5–treated (T) mice.
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ure 3F). Affi-5 did not influ-
ence the growth or viability of 
either human or murine RCC 
cells in normal or low serum 
or their release of CCR4 
ligands (data not shown).
RENCA cells labeled 
with luciferase were grown 
orthotopically in their synge-
neic hosts, WT BALB/c mice, 
by injection into the renal 
capsule of the left kidney. 
Mice reached humane end 
point during the course of 
tumor growth between 17 and 
21 days after implantation. 
Anti-CCR4 antibody treat-
ment significantly inhibited 
tumor burden as measured 
by tumor weight and biolu-
minescence as compared 
with treatment with an iso-
type control antibody (Figure 
2, B and C). Figure 2B shows 
the mean tumor weights at 
end point from 6 indepen-
dent experiments with 20 
mg/kg Affi-5 versus an iso-
type control, while Figure 2C 
shows a typical experiment 
using bioluminescence as a 
measure of tumor growth. 10 
mg/kg Affi-5 also had signif-
icant antitumor activity (Fig-
ure 2D). There was a signifi-
cant reduction in the serum 
concentration of the CCR4 
ligand CCL17 in treated mice 
(Figure 2E). In contrast, the serum concentration of CCL22 was 
low and did not change following treatment (Figure 2F). Analysis 
of CCL17 and CCL22 expression in tumor lysates showed that, 
adjusted for tumor size, CCL17 levels were stable while CCL22 
levels were higher in anti-CCR4–treated tumors (data not shown), 
suggesting that the decrease in CCL17 circulating levels might 
reflect a reduction in tumor size.
Actions of the anti-CCR4 antibody on TAMs. We considered 
based on the data presented previously, as well as the published 
literature, that the mechanism of anti-CCR4 inhibition on tumor 
growth could involve direct effects on malignant cells and/or 
on leukocytes. To investigate mechanisms of action of the anti-
CCR4 antibody, we studied single-cell suspensions from the 
treated tumors. Several cell types were positive for CCR4 staining 
in control tumors: macrophages (CD45+F4/80+CD11b+) and dif-
ferent T cell subtypes, such as CD4+ (CD45+CD3+CD4+FoxP3–), 
CD8+ lymphocytes (CD45+CD3+CD8+), and Tregs (CD45+CD3+ 
CD4+FoxP3+) (Supplemental Figure 4). NK cells were also weakly 
positive for CCR4 staining (Supplemental Figure 4). Compared 
obtained for A498 (data not shown) and murine RENCA cells 
(Supplemental Figure 3, A and B), with characteristic bell-shaped 
concentration-response curves typical of chemokine-mediated 
migration, implying that the receptor can be functional on malig-
nant cells. shRNA to CCR4 abolished CCR4 staining in the RCC 
cells as well as their migration to CCL17 (Supplemental Figure 3, 
C and D). In addition, a fully human anti-CCR4 antagonistic anti-
body, Affi-5 (19), abrogated the migration of 786-O cells to CCL17, 
further confirming that the CCR4 receptor is functional in the 
tumor cells (Supplemental Figure 3E).
Antitumor activity of an anti-CCR4 antibody. Taken together, 
the above data and the published literature suggest that CCR4 is a 
therapeutic target of interest in human solid cancers, especially as 
it is expressed by both malignant cells and tumor-infiltrating leu-
kocytes. We therefore conducted preclinical experiments using the 
Affi-5 antagonistic antibody to CCR4 in the RENCA mouse RCC 
model. Affi-5 inhibited migration of RENCA cells to murine CCL17 
and CCL22, showing that the antibody was antagonistic to murine 
CCR4 as well as human CCR4 (Figure 2A and Supplemental Fig-
Figure 3. Effects of anti-CCR4 on the RENCA TAMs. BALB/c mice were injected with RENCA-luc cells and treated with 
Affi-5 (T) or isotype control (C). Mice were sacrificed 17 days after surgery, and tumors were dissociated and character-
ized by flow cytometry. (A) Tumor-infiltrating macrophages (gated as CD45+CD11b+F4/80+) per milligram of tumor for 5 
independent experiments are shown. There was no significant difference between Affi-5–treated (T) and isotype- 
treated (C) tumors (n = 15 and n = 14, respectively). (B and C) Geometric mean of fluorescence intensity (MFI) for MHCII 
and MR staining on macrophages for 5 independent experiments, and staining for isotype-treated and Affi-5–treated 
dissociated tumors for 1 representative experiment. Two-tailed Student’s t test, ***P = 0.0008 and **P = 0.0085.  
n = 19 for C, n = 17 for T. (D) RNA was extracted from macrophages (CD45+CD11b+F4/80+) sorted by flow cytometry from 
dissociated tumors. The ratio between arginase and Nos2 expression was determined by real-time PCR in 2 independent 
experiments pooled together (Mann-Whitney U test, *P = 0.035), with n = 6 for C, n = 7 for T. (E) Cells were dissociated at 
end point from dissected tumors from BALB/c mice treated with Affi-5 (T) or isotype control (C) and plated overnight in 
the presence of brefeldin A. The fold change in the number of macrophages (CD45+CD11b+F4/80+) positive for intracellu-
lar TNF-α is shown from 2 pooled experiments (Mann-Whitney U test, **P = 0.002, n = 11 for C and n = 15 for T).
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inducible Nos2 expression. The arginase/Nos2 expression ratio was 
significantly lowered by anti-CCR4 treatment (Figure 3D). Purified 
Affi-5–treated macrophages also showed increased intracellular 
TNF, further evidence for an M1 cytotoxic phenotype (Figure 3E). 
Taken together, these data imply that the phenotype of macro-
phages from anti-CCR4–treated tumors was altered compared with 
isotype control–treated tumors and displayed several characteris-
tics associated with an antitumor response.
We next asked whether CCR4 inhibition could have similar 
activities in another mouse cancer model, testing Affi-5 in the B16 
melanoma model. As shown in Supplemental Figure 5, treatment 
altered the TAM phenotype, with a significant increase in MHCII 
in myeloid cells in 2 separate experiments (Supplemental Figure 
5A). There was, however, no effect on MR expression (Supplemen-
tal Figure 5B) or tumor weight (Supplemental Figure 5C) in this 
rapidly growing model.
Actions of the anti-CCR4 antibody on T cells in the tumor 
microenvironment. We next examined changes among the CD3+ 
T cells, which were also positive for CCR4 in the RENCA tumor 
with the leukocyte populations, CD45– cells, which contain the 
malignant cell population, were only weakly positive for CCR4 
(Supplemental Figure 4).
As TAMs showed expression of CCR4, we first studied the 
numbers and phenotype of these cells. The number of TAMs (gated 
as CD45+CD11+CD11b+F4/80+) per milligram of tumor did not dif-
fer significantly between Affi-5–treated and control-treated tumors 
(Figure 3A). However, the phenotype of the macrophages was 
affected by treatment. TAMs from Affi-5–treated mice expressed 
significantly higher levels of MHC class II (MHCII) and lower lev-
els of mannose receptor (MR) compared with TAMs from control- 
treated mice (Figure 3, B and C). In the spectrum of phenotype of 
macrophage activation, low MHCII expression and high MR levels 
are associated with an M2 phenotype, which promotes tissue repair 
and cell proliferation (20). Conversely, high MHCII expression and 
low MR expression are characteristic of an M1 macrophage pheno-
type, associated with antitumor activity. To further characterize the 
TAM phenotype, we extracted mRNA from macrophages from Affi-
5– and control-treated tumors and analyzed them for arginase 1 and 
Figure 4. Involvement of T cells in the actions of the anti-CCR4 antibody. BALB/c mice were injected with RENCA-luc cells and treated with Affi-5 (T) 
or isotype control (C). Mice were sacrificed 17 days after surgery, and tumors were dissociated and characterized by flow cytometry. (A and B) Number of 
CD45+CD3+ (A) and CD4+FoxP3+ (Tregs), CD4+ FoxP3– (CD4eff), and CD8+ (B) cells/mg of tumor in tumors from isotype-treated (C) or Affi-5–treated (T) mice for 
4 experiments pooled together. Two-tailed Student’s t test, (A) **P = 0.003 and (B) *P = 0.01 (Tregs and CD8), *P = 0.02 (CD4eff), with n = 15 for C, and n = 14 
for T). (C) Ratio of CD3+CD4+ FoxP3– or CD3+CD8+ to CD3+CD4+FoxP3+ (Treg) lymphocytes in isotype-treated and Affi-5–treated mice for 4 experiments. (D) Two 
control-treated (control) and 2 Affi-5–treated (treated) tumors from BALB/c mice were lysed, and an amount equivalent to 200 μg tumor lysate was incubated 
on Proteome Profiler Mouse Cytokine Array Panel A membranes. Average signal for each cytokine was normalized to signal from control-treated tumors. Fold 
change compared with control, grouped for Th1 cytokines and Th2 cytokines, is shown (2-tailed Student’s t test, P = 0.0173). (E and F) CD3 cells were isolated 
at end point from dissected tumors from BALB/c mice treated with Affi-5 (T) or isotype control (C). Lymphocytes were stimulated with PMA and ionomycin for 
4 hours in the presence of brefeldin A and stained for intracellular IFN-γ. The percentage of IFN-γ–positive CD4+ cells (E) or CD8+ cells (F) is represented. Two 
independent experiments pooled together are shown (2-tailed Student’s t test, *P = 0.028 for IFN-γ–positive CD4+ cells [E], n = 5 for C, n = 6 for T). (G) Percent-
age of CD8+ cells positive for granzyme B (GZMB) is represented, from 4 independent experiments.
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microenvironment. The number of CD3+ cells per milligram of 
tumor was significantly higher in Affi-5–treated tumors com-
pared with controls (Figure 4A). As CCR4 has been implicated 
in the recruitment of Tregs at tumor sites (12, 13), we hypothe-
sized that treatment with anti-CCR4 would reduce the number 
of CCR4+ Tregs, as observed in adult T cell leukemia patients 
treated with mogamulizumab (18). However, the number of 
Tregs per milligram of tumor was higher in anti-CCR4–treated 
tumors (Figure 4B). Also the number of CD4+ effector cells and 
CD8+ cells per milligram of tumor was increased with treatment 
(Figure 4B). As a result of these changes, the ratios of CD4+ T 
effector or CD8+ T cells to Tregs in tumors were unaffected by 
Affi-5 treatment (Figure 4C).
However, there was an increase in the amount of Th1 cyto-
kines compared with Th2 cytokines in the Affi-5–treated tumor 
lysates (Figure 4D), which could help explain the M2/M1 switch 
observed in the TAMs.
We next explored in more detail the phenotype of CD4+ 
effector and CD8+ cells. The number of CD4+ cells positive 
for IFN-γ expression was increased in treated tumors (Fig-
ure 4E), while it was unaltered for the CD8+ cells (Figure 4F). 
Moreover, CD8 staining for granzyme B was not significantly 
altered by treatment (Figure 4G). Collectively, these data suggested a 
role for CD4+ cells in the antitumor activity of the anti-CCR4 antibody.
Other treatment-induced changes to tumor-infiltrating leuko-
cyte populations. We observed repeatedly a significant increase 
in tumor NK cells as a proportion of total CD45+ cells (Figure 
5A), while the proportion of granzyme B–positive NK cells was 
not altered (data not shown). The effects on NK cells was due 
to changes in cell number, as a significant increase in terms of 
NK cells/mg tumor could be observed (P = 0.03) (Figure 5B). 
Also, myeloid-derived suppressor cells (MDSCs), characterized 
as CD45+CD11b+Gr1+, constituted a reduced percentage of the 
CD45+ infiltrate in tumors from treated compared with control 
mice (Figure 5C), as there were fewer granulocytic (Gr1hi) and 
monocytic (Gr1int) MDSCs in treated tumors. As for the MDSCs, 
there was some variability between experiments in terms of num-
bers of cells, so we expressed the results as fold change in cells/
Figure 5. Other effects of anti-CCR4 antibody in the RENCA tumor model. BALB/c mice were injected with RENCA-luc cells and treated with Affi-5 (T) or 
isotype control (C). Mice were sacrificed 17 days after surgery, and tumors or spleens were dissociated and characterized by flow cytometry. (A) Percentage of 
NK cells (CD45+CD3–DX5+) among the CD45+ population in tumors; 2-tailed Student’s t test, **P = 0.0064, 4 independent experiments pooled together  
(n = 12 for C, n = 15 for T). (B) The number of NK cells/mg of tumor was also significantly higher with treatment (2-tailed Student’s t test, *P = 0.032,  
n = 12 for C, n = 15 for T). (C) Percentage of MDSCs (CD45+CD11+Gr1+) among the CD45+ infiltrate for tumors from control and treated animals. Two popula-
tions of MDSCs (Gr1hi and Gr1int) were identified and analyzed separately. Two-tailed Student’s t test, **P = 0.0021 and ***P = 0.0065; 2 experiments pooled 
together, n = 7 for C and n = 6 for T. (D) The fold change in the number of MDSCs/mg of tumor was also significantly lower in the tumors from treated 
animals (4 experiments, 2-tailed Student’s t test, *P = 0.017, n = 12 for C, n = 11 for T). (E) Percentage of MDSCs (CD45+CD11b+Gr1+) among the CD45+ infiltrate 
for spleens from control and treated animals. Two populations of MDSCs (Gr1hiLy6Cint and Ly6ChiGr1int) were identified and analyzed separately. Two-tailed 
Student’s t test, P = 0.075 for Gr1hi, *P = 0.018 for Ly6Chi, n = 3. (F) Naive CD3+ cells isolated from spleen of healthy mice (5 × 104/well) were pre-labeled with 
CFSE and activated with anti-CD3– and anti-CD28–coated beads at a ratio 1:2 beads/CD3 cells in the presence of freshly isolated MDSCs from tumors. Cells 
were cocultured for 3 days, and CD4+ and CD8+ T cell proliferation was measured by CFSE dye dilution from 2 independent experiments, each pooling MDSCs 
from 2–3 tumors. Proliferation was inhibited significantly (1-way ANOVA, P = 0.0012 for CD4, P = 0.0058 for CD8, at MDSC/T cell ratios of 10:1, 1:1, 1:2).
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mg tumor. Pooling results from 4 experiments, we see a signifi-
cant reduction in treated tumors (P = 0.017) (Figure 5D). A similar 
reduction of granulocytic (Gr1hi) and monocytic (Ly6-Chi) MDSCs 
was seen in the spleen of treated mice compared with control mice 
(Figure 5E). To determine whether the accumulated CD11b+Gr1+ 
cells have a suppressive phenotype and could really be identified 
as MDSCs, we performed immunosuppression assays using T 
cells as effectors. Increasing amounts of MDSCs from the tumors 
of untreated mice effectively suppressed proliferation of activat-
ed CD4+ and CD8+ cells isolated from naive splenocytes (Figure 
5F). Similarly, splenic MDSCs isolated from tumor-bearing mice 
suppressed proliferation of CD4+ and CD8+ cells (data not shown).
Figure 6. Effects of anti-CCR4 on the RENCA tumors require CD4+ cells. (A–D) BALB/c nu/nu mice were injected with 1 × 105 RENCA-luc cells and treated 
with Affi-5 (T) or isotype control (C) (10 mg/kg) twice weekly starting 48 hours after surgery. Mice were sacrificed at 17 days after surgery, and tumor 
weight was determined (n = 9 C, n = 8 T, not significant). Geometric mean of fluorescence intensity for MHCII (B) and MR (C) staining on macrophages 
(CD45+CD11b+F4/80+), for isotype-treated and Affi-5–treated dissociated tumors; n = 4. (D) Percentage of NK cells (CD45+CD3–DX5+) among the CD45+ 
population; n = 4. (E–H) BALB/c mice were injected with 1 × 105 RENCA-luc cells and treated with Affi-5 (T) or isotype control (C) (10 mg/kg) twice weekly 
starting 48 hours after surgery. Treatment with anti-MHCII or the relevant isotype control (10 mg/kg) was started 1 day prior to surgery and continued 
with 3 doses per week. Mice were sacrificed 17 days after surgery, tumor weight was determined (n =6 for each group), and tumors were dissociated and 
characterized by flow cytometry. (E) Blocking of MHCII has a significant effect on tumor weight (2-way ANOVA, *P = 0.049). Bonferroni post-test showed 
significant difference (P < 0.05) in weight of Affi-5–treated tumors in the presence versus absence of anti-MHCII. (F and G) Geometric mean of fluores-
cence intensity (MFI) for MHCII (F) and MR (G) staining on macrophages (CD45+CD11b+F4/80+). There is a significant difference between MHCII and MR 
expression of macrophages from Affi-5–treated tumors in the presence or absence of anti-MHCII (Kruskal-Wallis test with Dunn post-test, *P < 0.05 and 
1-way ANOVA with Bonferroni post-test, **P < 0.001, with n = 3–4 for each group). (H) Percentage of NK cells (CD45+CD3–DX5+) among the CD45+ popula-
tion. There is a significant difference (1-way ANOVA with Bonferroni post-test, ***P < 0.001) in the percentage of NK cells from Affi-5–treated tumors in 
the presence versus absence of anti-MHCII.
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CCR4 antibody on RENCA tumor weight (Figure 6E), macrophage 
MHCII (Figure 6F), and MR expression (Figure 6G), and percent-
age of NK cells in the tumor microenvironment (Figure 6H).
We concluded that CD4+ T cells are essential mediators of 
the actions of the anti-CCR4 receptor antibody Affi-5, and were 
required for the observed changes in macrophage phenotype and 
proportion of NK cells.
CCR4 function in normal CD4+ T cells. Our results led us to 
question whether CCR4 might be involved in direct regulation of 
Th1 and Th2 responses in normal CD4+ T cells. To explore this, we 
developed an in vitro assay in which CD4+ T cells were purified 
from splenocytes of healthy mice and polarized to a Th1 response 
with IL-12 and IL-2 in the presence of anti-CD3 and anti-CD28 
Further investigation of CCR4 receptor on tumor CD4+ T cells. 
As in our model we observed changes to cells of both the adaptive 
and innate immune response, and some of our evidence pointed to 
involvement of CD4+ T cells, we wanted to better understand the 
interplay between these different components. Affi-5 did not inhib-
it RENCA tumor growth in T cell–deficient nude mice (Figure 6A), 
and there was also no effect on macrophage phenotype or extent 
of NK cell infiltrate in tumors in nude mice (Figure 6, B–D). This 
suggested that adaptive immunity, especially via CD4+ T cells, was 
upstream of the actions on the cells of the innate immune system.
To further investigate a role for CD4+ T cells in the antitumor 
actions of Affi-5, we combined this agent with a neutralizing anti-
body to MHCII. This completely abrogated the effects of the anti-
Figure 7. CCL17 can inhibit Th1 
responses in vitro. (A and B) CD4+ 
cells were isolated from spleens of 
healthy mice and stimulated with 
IL-2 and IL-12 in the presence of 
anti-CD3– and anti-CD28–coated 
beads. CCL17, CCL22, Affi-5 (10 μg/
ml), or isotype control was added 
after an overnight incubation; 
after 3 days cells were stimulated 
with cell stimulation cocktail, 
harvested, stained for intracel-
lular IFN-γ, and analyzed by flow 
cytometry. Results of 7 and 3 inde-
pendent experiments are shown 
for CCL17 and CCL22, respectively 
(A), together with representative 
plots of 1 experiment. Results of 
4 independent experiments are 
shown in B, with representative 
plots of 1 experiment. *P < 0.05, 
**P < 0.01, 1-way ANOVA with 
Bonferroni post-test.
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of ADCC in the actions of Affi-5. While 
it is possible that murine Fc receptors 
would interact with a human antibody 
(22), both a defucosylated (which was 
used in all the experiments present-
ed up to this point) and a fucosylated 
version of Affi-5 antibody had similar 
and significant antitumor effects (Fig-
ure 8A). Moreover, the CCR4 antago-
nist Affi-5 retained antitumor activity 
on RENCA cells in which CCR4 was 
silenced by shRNA (Figure 8, B and 
C). This result indicates that the anti-
tumor effect of Affi-5 occurs primarily 
through modulation of non-malignant 
cells in the tumor microenvironment. 
This is not entirely unexpected, since 
in vivo CD45– cells, which include 
RENCA cells, expressed low levels of 
CCR4 (Supplemental Figure 4). How-
ever, as this antibody has a reported 
ADCC activity against human lym-
phoma cells (19), it may act by ADCC 
on other tumor cells where CCR4 
expression is higher.
Levels of PD-L1 and CTLA4 after 
treatment. Immune checkpoint tar-
geting has proven to be a promising 
approach in the treatment of RCC. 
Therefore, we investigated wheth-
er the anti-CCR4 treatment had 
an impact on immune checkpoint 
ligands. As shown in Supplemental 
Figure 7, CTLA4 expression on Tregs, 
and PD-L1 expression on macro-
phages, CD3+ T cells, and CD45– cells, 
was retained after anti-CCR4 treat-
ment. This would suggest that, as the anti-CCR4 treatment dis-
plays actions on different components of the immune infiltrate, it 
could be a good candidate to be administered together with prom-
ising immune checkpoint inhibitors.
Discussion
In this study, we provide a comprehensive analysis of the 
expression of the chemokine receptor CCR4 and its ligands 
CCL17 and CCL22 in a solid tumor. We present evidence that 
CCR4 is expressed at significant levels in renal cancer biopsies, 
where it is associated with the extent of immune infiltrate. Also, 
expression of CCL17 and CCL22 is altered in renal cancer tis-
sue and in the plasma of patients. In fact, a high CCL17/CCL22 
ratio in plasma is associated with a worse prognosis. This is 
reminiscent of what has been observed in other solid tumors, 
where there is high CCR4 expression that is generally associat-
ed with a poor prognosis (14, 15). CCL22 is also detected in the 
tumor microenvironment of ovarian, hepatocellular, and breast 
cancer (10, 12, 13). Our work is further supported by a recent 
multivariate analysis of CCR4 expression in 53 RCC patient 
beads. This treatment stimulated production of IFN-γ over the 
course of 3 days. When CCL17 was added to the CD4+ cells 1 day 
after the initial stimulation, a significant reduction in the produc-
tion of IFN-γ was observed (Figure 7A). Although CCL22 produced 
a similar trend, it was markedly weaker than CCL17 in inhibiting 
Th1 polarization (Figure 7A). The action of CCL17 on CD4+ cells 
in vitro was abolished by addition of the anti-CCR4 antibody 
(Figure 7B). These results indicate that CCL17 might play a role 
in directly inhibiting the Th1 response, and provide more mecha-
nistic insight into the action of Affi-5. CCL17 in the tumor micro-
environment might be secreted by many cell types, including M2- 
polarized macrophages (21). To support this hypothesis, we mea-
sured mRNA levels for Ccl17 and Ccl22 in the different cell popu-
lations of the tumor microenvironment. Macrophages showed the 
highest expression of the two chemokines (Supplemental Figure 6), 
although a contribution from other cell types cannot be excluded.
Is ADCC involved in the antitumor action of the anti-CCR4 anti-
body? Finally, as ADCC is implicated in the mechanisms of action 
of the anti-human CCR4 antibody currently used clinically in treat-
ment of hematological malignancies (16), we investigated the role 
Figure 8. Effects of anti-CCR4 antibody are not dependent on malignant cell expression of CCR4. (A) BALB/c 
mice were injected with 1 × 105 RENCA-luc cells and treated with defucosylated Affi-5 (T; D), fucosylated Affi-5 
(T; F), or defucosylated isotype control (C) at 10 mg/kg twice weekly starting 48 hours after surgery. Mice were 
sacrificed 17 days after surgery, and tumor weight was analyzed (n = 7 C, n = 8 T [D], n = 7 T [F]). Two-tailed Stu-
dent’s t test, **P < 0.01, *P < 0.05. (B) RENCA-luc cells were infected with lentivirus encoding for non-silencing 
shRNA, or anti-CCR4 shRNA. Silencing of the infected cells lines was verified at the RNA level by real-time 
PCR. (C) BALB/c mice were injected with 1 × 105 RENCA-luc cells infected with a non-silencing lentivirus, or 
CCR4 shRNA (shCCR4), and treated twice weekly with Affi-5 at 10 mg/kg (T) or isotype control (C), starting 
48 hours after surgery; n = 6 for each group. Mice were sacrificed 17 days after surgery, and tumor weight was 
recorded. Affi-5 treatment had an effect (2-way ANOVA, P = 0.0036), and CCR4 silencing did not interact 
significantly with the Affi-5 treatment (P = 0.64).
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systemic depletion was successful, we never obtained a satisfac-
tory depletion in the tumor microenvironment. As proven by the 
experiment in nude mice, these multiple effects are not directly 
mediated by leukocytes of the innate immune system, but are 
dependent on the adaptive immune system. Moreover, disrupting 
the MHCII-TCR interaction abolished the therapeutic effect of 
the anti-CCR4 antibody and also impacted innate immunity, thus 
proving an essential role for CD4+ cells, linked to their ability to 
secrete IFN-γ. Our in vitro assay further supported the hypothesis 
that the CCR4/CCL17 axis may be involved in maintaining Th2 
responses. To our knowledge, the effects described here of CCR4 
inhibition in this tumor microenvironment are novel.
We had also predicted that the anti-CCR4 antibody Affi-5 may 
have ADCC activity in the RENCA model, especially on the malignant 
cells, but the RENCA cells in vivo had low expression of CCR4. CCR4 
is strongly expressed in several human T cell malignancies. Mogamu-
lizumab (KW-0761; Poteligeo), a humanized fucosylated anti-CCR4 
antibody that markedly enhances ADCC, is used in the treatment of 
patients with relapsed or refractory CCR4-positive ATL in Japan (26). 
Recently it also received approval in Japan for relapsed or refractory 
CCR4-positive peripheral T cell lymphoma (PTCL) and cutaneous 
T cell lymphoma (CTCL). We could find no evidence that Affi-5 was 
working via ADCC in our model system, but this does not preclude 
such an action in other models or patients where malignant cells have 
higher levels of CCR4. Neither, we would suggest, does it preclude 
mogamulizumab having other actions in the tumor microenviron-
ment. Nor could we find evidence that the anti-CCR4 antibody had 
direct effects on the CCR4-expressing malignant cells. This may be 
because the CD45– population, which contained the malignant cells, 
expressed low levels of CCR4 in the tumor microenvironment. In 
addition, RENCA tumors growing in nude mice did not respond to the 
anti-CCR4 antibody. As anti-CCR4 inhibited RENCA cell migration 
in vitro, it is possible that the antibody had an antimetastatic effect, but 
it was not possible to measure this in our model system.
In summary, we have described here a therapeutic strategy to 
target solid tumors with significant CCR4 expression in the tumor 
microenvironment. As targeting CCR4 in hematological malig-
nancies has shown manageable side effects, this approach could 
readily be translated into the clinic. Moreover, this opens the pos-
sibility for evaluation of combinations of CCR4 inhibition with oth-
er immune-modulatory agents. Inhibition of CCR4 had multiple 
actions in the RCC experimental tumor microenvironment — but 
predominantly there was evidence of a Th2/M2 to Th1/M1 switch. 
CCR4 inhibition also increased MHCII expression on TAMs in the 
B16 model. As neither Treg infiltration nor CD8 activation was 
affected and the antibody did not alter levels of CTLA4 and PD-L1 
in the renal tumor microenvironment, there is a strong rationale for 
a combination with immune checkpoint blockade. Also combina-
tions with anti-CD40 agonistic antibodies would be an attractive 
option, as stimulating macrophage activation in a Th1-skewed envi-
ronment may increase a host antitumor response.
Methods
Reagents. Recombinant human chemokines CCL17 (catalog 300-30) 
and CCL22 (catalog 300-36) were purchased from Peprotech. Recom-
binant mouse CCL17 (529-TR) and CCL22 (439-MD) were purchased 
from R&D Systems.
biopsies, where CCR4 expression was an independent risk fac-
tor for poor prognosis and overall survival (23). Taken together, 
these observations suggest that CCR4 is an attractive therapeu-
tic target in solid cancers.
In the current work, we have not considered a role for the 
chemokines CCL2 and CCL5, which may also bind to CCR4, as 
CCL17 and CCL22 have the highest affinity for the receptor, but in 
future studies it would be interesting to assess the effect of CCR4 
inhibitions on their local and systemic levels.
In this study we report for the first time to our knowledge 
that an anti-CCR4 antibody has activity in a solid cancer model. 
As CCR4 is expressed on a number of different immune cells, we 
had expected that the CCR4 antibody would reduce the num-
ber of tumor-infiltrating leukocytes as part of its mechanism of 
action, but this did not occur. In particular, we did not observe 
an effect on the number of infiltrating Tregs, which are thought 
to be recruited though CCR4 in the tumor microenvironment of 
different tumor types (11–13). In fact, the antibody caused unex-
pected changes in the phenotype of myeloid cells in the RENCA 
tumor microenvironment from potentially pro- to antitumor. 
TAMs mainly consist of a population with little cytotoxicity 
for tumor cells because of their limited production of NO and 
proinflammatory cytokines. At the same time, TAMs also pos-
sess poor antigen-presenting capability (20). This has led to the 
notion that depleting TAMs from the tumor microenvironment 
is an interesting target in cancer therapy. However, it was shown 
recently that inhibition of the macrophage cell surface receptor 
CSF1R with a small molecule inhibitor in a model of glioblasto-
ma was able to reduce tumor progression by reducing the M2 
polarization of TAMs (24). This work proved that modification of 
TAM tumor-promoting functions may have a significant impact 
on tumor growth and that depletion is not strictly necessary for 
an effective TAM-targeted therapy. In our work, the use of an 
anti-CCR4 antibody achieved, through a different mechanism 
of action, a similar change of TAM phenotype, which resulted 
in a reduction of tumor growth. Findings in human renal cancer 
provide an interesting correlate to our experimental data, sug-
gesting that stimulating an M2/Th2 to M1/Th1 response may 
be of therapeutic value. In a recent analysis of the intratumor-
al immunologic profile of RCC biopsies, the expression of M2 
macrophage markers correlated with a poor prognosis and high 
tumor NOS2 mRNA levels with a good prognosis (25). To con-
firm the importance of macrophages in the mechanism of action 
of Affi-5, a depletion experiment with clodronate liposomes was 
set up, but the partial depletion of the macrophages was accom-
panied by an M1 polarization of the remaining macrophages 
(data not shown), thus invalidating this model for testing our 
hypothesis. The potential of the anti-CCR4 antibody was also 
suggested in the B16 melanoma experiments, where we found 
an increase in MHCII expression. However, this “partial switch” 
was not enough to generate an antitumor effect.
As part of the multiple effects of the anti-CCR4 antibody, we 
also observed a significant increase in NK cells, as well as reduc-
tion in MDSCs and circulating CCL17, which can additionally con-
tribute to decreased tumor growth. To determine the contribution 
of these different populations infiltrating the tumors, we attempt-
ed to deplete NK cells and MDSCs in this model. However, while 
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with Diff-Quik (Dade Behring). For each insert, the number of migrat-
ed cells/field (40× for 786-O, 20× for RENCA) was determined. The 
assays were performed in triplicate.
Anti-CCR4 antibody. Affi-5 is a human IgG1 antibody antagonist 
of CCR4. This antibody is also referred to as 503 (18). It was produced 
by transient transfection of expression vectors into HEK293T cells with 
FuGENE transfection reagent (Promega). The ADCC enhanced (defu-
cosylated) variant was produced using a selective class I α-mannosidase 
inhibitor, kifunensine (Sigma-Aldrich), that was added to the culture 
medium at a concentration of 100 ng/ml. The antibody was then purified 
using standard conditions and formulated in 20 mM PBS, 145 mM NaCl, 
pH 7.2. It was diluted to the required concentration in the same buffer.
In vivo experiments. For the renal model, 6- to 8-week-old 
female BALB/c or BALB/c nu/nu mice from Charles River Lab-
oratories were injected orthotopically with 1 × 105 luciferase- 
labeled RENCA cells resuspended in Matrigel (354248, BD Bio-
sciences, Becton Dickinson) into the renal capsule of the left kid-
ney. Affi-5 and the appropriate isotype control were injected i.p. 
twice weekly at 10 or 20 mg/kg, starting on day 2 after surgery. 
Tumor weight was determined at the end of the experiment by 
subtracting the right kidney weight from the weight of the tumor- 
bearing left kidney.
Tumor growth was monitored after administration of luciferin 
(3 mg/mouse, Sigma-Aldrich) with the IVIS Imaging System 100 (Xenogen 
Biosciences). Mice were sacrificed between days 17 and 12 after surgery.
The anti-MHCII blocking antibody (clone M5/114) and the iso-
type control (LTF-2) were obtained from BioXCell and administered 
i.p. at 10 mg/kg 1 day prior to surgery and 3 times/week thereafter.
For the melanoma model, 8- to 12-week-old C57BL/6 mice from 
Charles River Laboratories were injected subcutaneously with 1 × 105 
B16F0 cells resuspended in PBS. Affi-5 and the appropriate isotype 
control were injected i.p. twice weekly at 20 mg/kg, starting on day 2 
after surgery. Mice were sacrificed on day 18 after injection.
Flow cytometry and sorting. Human cell lines were dissociated 
using cell dissociation buffer (Invitrogen) and stained with anti-
CCR4 (R&D Systems, FAB1567P) or IgG2B isotype control (R&D 
Systems). After washing, cells were incubated with Alexa Fluor 
594–anti-mouse antibody (Invitrogen). Intracellular staining was 
achieved using saponin permeabilization before antibodies against 
CCL17 and CCL22 were applied (R&D Systems, IC364IP and 
IC3361P, respectively). RENCA murine cells were stained with Affi-
5 or isotype control. After washing, cells were incubated with Alexa 
Fluor 488–anti-human antibody (Invitrogen).
Tumor-bearing left kidneys were chopped and incubated in 2 mg/
ml collagenase V (Sigma-Aldrich), and 25 μg/ml DNAse (Roche), in 
HBSS (Sigma-Aldrich) for 45 minutes at 37˚C, 5% CO2. Tumor-bearing 
kidneys were selected to be representative of the average tumor weight 
of the treatment group they belonged to. The lysate was strained with 
70-μm strainers (Fisher Scientific), and red blood cells were lysed (BD 
Pharm Lyse, BD Biosciences). Cells were counted, and 6 × 106 cells were 
stained in PBS + 2% heat-inactivated FBS + 2 mM EDTA after blocking 
with αCD16/CD32 (14-0161, eBioscience) for 15 minutes. Staining anti-
bodies were diluted 1:200 unless otherwise specified: αCD45 (48-0451, 
eBioscience), αFoxP3 (56-5773, eBioscience), αCD3 (45-0031, eBiosci-
ence), αCD4 (560783, BD Biosciences, 1:300), αCD8 (48-0041, eBiosci-
ence, 1:300), αLy6-C (45-5932, eBioscience), αLy6-G (referred to here 
as Gr1) (35-5931, eBioscience), αCD49b (108918, BioLegend), αF4/80 
RNA isolation and real-time PCR. RNA from sorted macrophages 
was extracted with the RNeasy Micro Kit (QIAGEN) and ampli-
fied with the Ovation PicoSL WTA System V2 (NuGEN). Real-time 
RT-PCR analysis was performed using TaqMan assays (Applied Bio-
systems) — CCR4 (Hs99999919_m1), 18S (4310893E), arginase 1 
(Mm00475988_m1), Nos2 (Mm00440502_m1) — with the ABI Ste-
pOnePlus instrument (Applied Biosystems).
Renal tissue and patient plasma samples. Patients samples were 
collected from patients who had locally advanced or metastatic RCC, 
who had progressed after first-line cytokine-based therapy (for locally 
advanced disease), or who were intolerant to first line cytokine-based 
therapy (for locally advanced or metastatic disease). The TMA mainly 
comprised clear cell renal carcinomas (75%), with some biopsies clas-
sified as papillary renal cancer. Clear cell renal carcinomas were iden-
tified using standard IHC and carbonic anhydrase IX (CAIX) staining. 
CCR4 was detected on the malignant cells from 153 of 173 malignant 
tumors, clear cell and non–clear cell, in our TMA. Controls were age-
matched individuals with no malignancies.
IHC. Paraffin-embedded sections (4 μm) were dewaxed and dehy-
drated, and antigen retrieval was performed by microwaving sections 
in Antigen Unmasking Solution (Vector Laboratories, H-3300) for 9 
minutes. After blocking with the appropriate serum, samples were 
incubated overnight at 4°C using primary antibodies: CCR4 (ab1669 
1:300; Abcam), CCL17 (ab182793 1:100; Abcam), CCL22 (500-P107 
1:20; Peprotech), CD3 (A0452, 1:100; Dako), CD68 (M0876 1:50; 
Dako). Following incubation with a biotinylated secondary antibody 
(anti-goat, anti-rabbit, or anti-mouse IgG, 1:200; Vector Laborato-
ries) for 30 minutes at room temperature, antigens were revealed 
with 3,3ˇ-diaminobenzidine (Sigma-Aldrich). Omission of the primary 
antibody and isotype control antibody were used as negative controls. 
The scoring for intensity of staining on positive cells was as follows: 0 
(no expression), 1 (low expression), and 2 (high expression).
ELISA and Meso Scale Discovery System. Human CCL17 and 
CCL22 were determined from plasma with Meso Scale Discovery 
System plates (Human TARC Ultra-Sensitive Kit, K151BGC-1; and 
Human MDC Ultra-Sensitive Kit, K151BAC; Meso Scale Diagnostic). 
Mouse CCL17 and CCL22 were determined from plasma or serum 
with Mouse CCL17/TARC Quantikine ELISA Kit (MCC170) or Mouse 
CCL22/MDC Quantikine ELISA Kit (MCC220) from R&D Systems.
Cell culture. 786-O and B16F0 cells were obtained from ATCC, while 
RENCA used in the in vivo experiments were a gift from Robert Wiltrout 
(NCI’s Frederick Cancer Research and Development Center, Bethesda, 
Maryland) or were obtained from ATCC for the in vitro experiments. 
Cells were incubated at 37°C in humidified air with 5% CO2. 786-O cells 
were cultured in RPMI culture media containing 10% FBS, 1% penicillin/
streptomycin (p/s), and 1% glutamine. RENCA culture medium was fur-
ther supplemented with 1% glutamine and 1 mM sodium pyruvate. Renal 
cancer cell lines were luciferase labeled for in vivo experiments. B16F0 
cells were cultured in DMEM containing 10% FBS and 1% p/s.
Migration assays. Chemotaxis was assayed using Falcon PET Cell 
Culture Inserts, 8-μm pore (353182, Becton Dickinson). 786-O cells 
were seeded in the upper chamber at 1 × 105 in 0.5 ml serum-free 
RPMI, and 1 ml of medium alone or supplemented with recombinant 
chemokines was added to the lower chamber. RENCA cells were 
seeded at 2 × 105 in medium containing 1% serum. After overnight 
incubation at 37°C and 5% CO2, cells on the upper surface of the filter 
were removed and migrated cells on the lower surface were stained 
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Brefeldin A (20 μg/ml, Sigma-Aldrich) for 3 hours. At the end of the 
incubation, cells were washed; blocked as above; stained with αCD3 
(45-0031, 1:200), αCD8 (48-0041, 1:300), αCD4 (47-0041, 1:200), 
from eBioscience, and Fixable Viability Dye eFluor 506, 1:1,000; fixed 
in 2% formalin; and stored overnight at 4°C. The day after, cells were 
permeabilized and stained with αIFN-γ (17-7311, 1:100) and αTNF (11-
7321-81, 1:75), or the appropriate isotype controls, from eBioscience, 
in 25 μl in permeabilization buffer for 30 minutes at 4°C, and further 
processed and analyzed as specified above.
Cytokine expression. Frozen tumors were lysed with a gentleMACS 
M tube (Miltenyi Biotec) in PBS with Complete Protease Inhibitors 
(Roche). Triton X-100 was added (1%), and lysates were cleared by 
centrifugation and applied to Proteome Profiler Mouse Cytokine 
Array Panel A membranes (R&D Systems). An equivalent amount of 
200-μg tumor lysate was incubated according to the manufacturer’s 
instructions. Film exposures were quantified using NIH ImageJ soft-
ware, subtracting a lane background.
In vitro Th1 polarization assay. Splenocytes from healthy BALB/c 
mice were obtained by mashing spleens through a 70-μm strainer 
and lysis of red blood cells. CD4+ cells were purified with the Miltenyi 
Biotec CD4+ T cell purification kit according to the manufactur-
er’s instructions. CD4+ cells were resuspended in Iscove’s modified 
DMEM (10%FBS, 50 μM β-mercaptoethanol, 8 mM glutamine) and 
stimulated with 1:1 Dynabeads Mouse T-Activator CD3/CD28 (Invi-
trogen), mouse IL-2 20 ng/ml, and mouse IL-12 5 ng/ml (from R&D 
Systems). The day after, the indicated concentrations of CCL17 or 
CCL22 in combination with Affi-5 (30 μg/ml) were added to the plate. 
Experiments with Affi-5 were performed in Corning Ultra-Low attach-
ment plasticware (Corning Life Sciences). Cells were stimulated with 
restimulation cocktail plus transport inhibitor from eBioscience for 5 
hours and stained for 30 minutes at 4°C with αCD16/CD32 (14-0161, 
eBioscience, 1:200), Fixable Viability Dye eFluor 450 1:1000, αCD4 
(560783, BD Horizon CD4, BD Biosciences, 1:300) in 50 μl FACS buf-
fer. After washing, cells were permeabilized and stained with αIFN-γ 
(17-7311, eBioscience, 1:100) or isotype control. After washing, cells 
were analyzed using a BD LSR Fortessa cytometer.
Immunofluorescence. Renal carcinoma 786-O and RENCA cells 
were cultivated on a chamber slide (Nalge Nunc International) for 1–2 
days. Cells were then fixed for 30 minutes with 4% formaldehyde and 
permeabilized with 0.5% Triton X-100 in PBS for 10 minutes. Sam-
ples were blocked with 1% BSA for 2 hours at room temperature, then 
incubated overnight at 4°C with 25 mg/ml αCCR4 (IMG-322, IMGEN-
EX, Novus Biologicals). After washing, samples were incubated with 
Alexa Fluor 594–conjugated secondary antibody, 1:2,000, for 2 hours 
at room temperature. Finally, samples were washed and mounted with 
ProLong Gold DAPI (Invitrogen, P36931). Cells were then visualized 
using a Zeiss LSM510 confocal microscope.
RNA interference for CCR4 in renal cancer cell lines. Commercially 
available shRNAs, based on the pRS vector, were purchased from Ori-
gene Technologies. Four non-overlapping sequences were provided 
to target human (TR314127) and mouse (TR500386) CCR4. A non-
specific shRNA sequence (shGFP, TR30003) and empty pRS vector 
(TR20003) served as controls. Phoenix packaging cell line was trans-
fected overnight with LipofectAMINE 2000 (Invitrogen) and 5 μg of 
the shRNA plasmid DNA. After an incubation with complete medium 
at 33°C and 5% CO2 for 16 hours, the supernatant was collected, fil-
tered, and diluted 8:10 in RCC medium with the addition of Polybrene. 
(47-4801, eBioscience, 1:150), αCD11b (11-0112, eBioscience), αMMR 
(141706, BioLegend), αMHCII (17-5321, eBioscience), αCCR4 (131214, 
BioLegend), αCD4 (560783, BD Biosciences, 1:300), αKi-67 (612472, 
BD Biosciences, 5 μl/staining). Appropriate isotype control antibodies 
were used to generate fluorescence minus one (FMO) controls. Viability 
was assessed with Fixable Viability Dye eFluor 780 or 506 (eBioscience) 
diluted 1:1,000. Staining was performed for 30 minutes at 4°C. Cells 
were washed, fixed in 2% formaldehyde, and analyzed using a BD LSR 
Fortessa cytometer. Analysis was performed with FlowJo software.
For the sorting of TAMs, tumors were dissected and dissociated as 
described above. Cells were stained in PBS + 2% heat-inactivated FBS + 2 
mM EDTA after blocking with αCD16/CD32 (14-0161, eBioscience) for 
15 minutes. Staining antibodies were from eBioscience and were dilut-
ed 1:200 unless otherwise specified: αCD45 (catalog 48-0451), αLy6-G 
(Gr1) (catalog 35-5931), αF4/80 (catalog 47-4801, 1:150), αCD11b (cata-
log 11-0112), for 30 minutes at 4°C. DAPI (2.5 μg/ml) was added prior to 
sorting, which was performed with a BD FACSAria II cell sorter.
Suppression assay. Tumors were dissociated as for flow cytometry 
staining and pooled. MDSCs were purified according to the manu-
facturer’s instructions using the Myeloid-Derived Suppressor Cell 
Isolation kit (Miltenyi Biotec). Naive CD3+ cells were isolated from 
spleens of healthy mice using the Dynabeads FlowComp Pan T kit 
(Invitrogen). Before stimulation, CD3+ cells were pre-labeled with 5 
μM CSFE (eBioscience) for 5 minutes at 37°C in medium and washed. 
Some of the cells were left without stimulus, while the remaining cells 
were stimulated with anti-CD3/anti-CD28–coated beads (Dynabeads 
Mouse T-Activator CD3/CD28, Invitrogen) at a ratio of 1:2 (beads/
CD3) and plated (5 × 104/well) in round-bottom 96-well plates. 
MDSCs were added to the wells at 10:1, 1:1, 1:2, and 1:8 ratios (CD3/
MDSCs) and incubated for 3 days. At the end of the incubation peri-
od, cells were collected and stained for viability, CD11b, CD3, CD4, 
and CD8 and analyzed by flow cytometry. Staining was performed for 
30 minutes at 4°C. Cells were washed, fixed in 2% formaldeyde, and 
analyzed using a BD LSR Fortessa cytometer. Analysis was performed 
with FlowJo software. CD4+ or CD8+ cells that had undergone at least 
one cycle of cell division were gated as proliferating.
Intracellular flow cytometry. Tumors were dissected and dissoci-
ated as described above. For macrophage staining, cells were plated 
(0.5 × 106/500 μl in a 24-well plate) and incubated overnight with 
Brefeldin A (Sigma-Aldrich), 20 μg/ml. The following day, cells were 
stained in PBS + 2% heat-inactivated FBS + 2 mM EDTA after block-
ing with αCD16/CD32, 1:200 (14-0161, eBioscience) for 15 minutes. 
Staining antibodies were from eBioscience and were diluted 1:200 
unless otherwise specified: αCD45 (catalog 48-0451), αLy6-G (Gr1) 
(catalog 35-5931), αF4/80 (catalog 47-4801, 1:150) αCD11b (catalog 
11-0112), and Fixable Viability Dye eFluor 780 or 506 (eBioscience) 
diluted 1:1,000 for 30 minutes at 4°C. After washing, cells were fixed 
in Intracellular Fixation Buffer (eBioscience) for 20 minutes at room 
temperature. Cells were further permeabilized and stained in perme-
abilization buffer with αTNF (11-7321-81, eBioscience) 1:75 in 25 μl, or 
the appropriate isotype control, for 30 minutes at 4°C. After washing, 
cells were analyzed using a BD LSR Fortessa cytometer. Analysis was 
performed with FlowJo software. For CD4/CD8 staining, lymphocytes 
were purified using Dynabeads FlowComp Mouse Pan T (Invitrogen) 
according to the instructions, plated in 500 μl in a 24-well plate, incu-
bated with PMA (50 ng/ml, Sigma-Aldrich) and ionomycin (1 μg/ml, 
Sigma-Aldrich) for 1 hour, and further incubated in the presence of 
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